Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company’s LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Metrics to compare | LIXT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLIXTPeersSector | |
---|---|---|---|---|
P/E Ratio | −7.4x | −3.6x | −0.5x | |
PEG Ratio | −0.21 | 0.00 | 0.00 | |
Price/Book | −10.5x | 2.6x | 2.6x | |
Price / LTM Sales | - | 158.4x | 3.3x | |
Upside (Analyst Target) | - | 114.9% | 43.5% | |
Fair Value Upside | Unlock | −1.0% | 6.3% | Unlock |